[ORGANIZATION]
NAION
Featured in 1 tracked story · first seen
Situations
GLP-1 drugs: clinical trends, safety, and market shifts
260 clusters · 952 sources · last updated
Latest: Novo Nordisk and Eli Lilly face lawsuits over alleged GLP-1 vision loss risks
Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr